Health Condition 1: K740- Hepatic fibrosis
Conditions
Interventions
Intervention1: DRUG TRIAL SAROGLITAZOR VS VITAMIN E NAFLD related cACLD: patient with NAFLD related cACLD are given saroglitazor and VITAMIN E along with life style modification
Intervention2: Sarogl
Sponsors
PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age18-75years 2. Patients with NAFLD: Defined by the presence of hepatic steatosis on ultrasound or using CAP parameters (of FibroScan) in absence significant consumption of alcohol ( 3. Patients with LSM > 10kPa 4. Consent to participate in study
Exclusion criteria
Exclusion criteria: 1. Patients 2. Patients with Hepatic decompensation 3. Patients with HCC or any other malignancy 4. Patients with concomitant other aetiologies for hepatic steatosis/fibrosis or elevated transaminases 5. Patients already on Vitamin E or pioglitazone 6. Pregnancy/Lactation and those non pregnant female patients recruited in the study who will conceive during the study period will be excluded from the study. 7. Patients who are too sick to conduct the protocol. 8. Those who do not consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcomes: Improvement in the hepatic fibrosis in patients with NAFLD related compensated advanced chronic liver disease at the end of 6 months. Timepoint: Primary Outcomes: Improvement in the hepatic fibrosis in patients with NAFLD related compensated advanced chronic liver disease at the end of 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in Hepatic fat fraction Improvement in MRE Improvement in FAST and MAST scores Improvemnt in ALT Improvement in Agaile 3+ and Agile 4 scoreTimepoint: at the end of 6 months | — |
Countries
India
Contacts
Public ContactGANESH C P
PGIMER Chandigarh
Outcome results
None listed